Promising efficacy and a low rate of cytokine release syndrome with ABBV-383 in patients with released/refractory multiple myeloma

Dr Muhamed Baljevic is a haematologist at the Vanderbilt University Medical Center, in Nashville, Tennessee (USA). In this vide, he discusses the results of a phase 1b study evaluating different doses of the anti-BCMA, anti-CD3 bispecific antibody ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM). This study revealed that a single step-up dose (SUD) of 2 mg ABBV-383 followed by a full dose of 60 mg in combination with a modified dexamethasone regimen reduced the incidence of cytokine release syndrome (CRS) to 30% (26% grade 1, 4% grade 2). Furthermore, preliminary efficacy results with this dosing schedule indicated a high rate of early treatment responses. Based on these results, future studies with ABBV-383 will adopt a dosing schedule using a 2 mg SUD in combination with modified dexamethasone premedication.